Infliximab Drug Level ELISA (IDKmonitor®)

Product code: K9655 (96 wells)

Determination of free therapeutic infliximab

Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). The IDKmonitor Infliximab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free infliximab in plasma or serum samples. Not all patients respond equally to infliximab, and this test helps to stratify patients according to whether they are likely to benefit from treatment or not, allowing clinicians to evaluate the drug efficacy and investigate primary non-response and loss of response.

​​​​The assay is widely available throughout the UK and Ireland to both routine clinical laboratories as well as for research applications. Please contact us for your nearest test reference laboratory. This kit is supported by UK publications and evidence base.

Key Advantages

Highly specific quantification of infliximab, with no cross reaction with adalimumab, golimumab and other plasma proteins
Total incubation time 130 minutes
Saves costs by predicting efficacy of infliximab treatment and stratifying patients accordingly
Applicable to both gastroenterology and rheumatology
Reportable range 0.53-45 ug/ml
Automatable on ELISA automates (e.g. Dynex DS2)



40 tests

Storage: 2-8 °C

Blood sample

Related Products

    Infliximab Total Anti-drug ELISA (IDKmonitor®)

    Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response. The IDKmonitor Infliximab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating drug.